OBJECTIVES: To develop a hitherto unavailable risk factor model for accurately predicting anemia development in cancer patients before chemotherapy (CT) administration. METHODS: 2,070 nonanemic patients from the European Cancer Anaemia Survey (ECAS) with hemoglobin (Hb) > or =12 g/dl at enrollment who received their first CT during ECAS and underwent at least two CT cycles were divided randomly into split half (SH) 1 and SH2 (n = 1,035 each). The model was developed on SH1 using logistic regression to simultaneously evaluate predictive factors, and was validated using SH2 and an additional similar subpopulation of 5,901 ECAS patients. Anemia risk values were assigned to the predictive factors and the sum of the predictive factors gave the total anemia risk score; lower-, higher-, and highest-risk cutoff points of the total anemia risk score were determined. RESULTS: Variables ultimately identified as significant predictive factors for anemia were: lower initial Hb (< or =12.9 g/dl in females, and < or =13.4 g/dl in males); having lung or gynecologic cancer versus gastrointestinal (GI)/colorectal cancer; cancer at any other site versus GI/colorectal cancer; treatment with platinum CT, and female gender. CONCLUSION: Using this evidence-based risk model, nonanemic patients who are at the highest risk of developing anemia prior to receiving CT can be identified clinically, allowing appropriate anemia management to be planned. Copyright 2006 S. Karger AG, Basel.
OBJECTIVES: To develop a hitherto unavailable risk factor model for accurately predicting anemia development in cancerpatients before chemotherapy (CT) administration. METHODS: 2,070 nonanemic patients from the European Cancer Anaemia Survey (ECAS) with hemoglobin (Hb) > or =12 g/dl at enrollment who received their first CT during ECAS and underwent at least two CT cycles were divided randomly into split half (SH) 1 and SH2 (n = 1,035 each). The model was developed on SH1 using logistic regression to simultaneously evaluate predictive factors, and was validated using SH2 and an additional similar subpopulation of 5,901 ECAS patients. Anemia risk values were assigned to the predictive factors and the sum of the predictive factors gave the total anemia risk score; lower-, higher-, and highest-risk cutoff points of the total anemia risk score were determined. RESULTS: Variables ultimately identified as significant predictive factors for anemia were: lower initial Hb (< or =12.9 g/dl in females, and < or =13.4 g/dl in males); having lung or gynecologic cancer versus gastrointestinal (GI)/colorectal cancer; cancer at any other site versus GI/colorectal cancer; treatment with platinum CT, and female gender. CONCLUSION: Using this evidence-based risk model, nonanemic patients who are at the highest risk of developing anemia prior to receiving CT can be identified clinically, allowing appropriate anemia management to be planned. Copyright 2006 S. Karger AG, Basel.
Authors: Leila Family; Lanfang Xu; Hairong Xu; Kimberly Cannavale; Olivia Sattayapiwat; John H Page; Chet Bohac; Chun Chao Journal: Support Care Cancer Date: 2016-05-11 Impact factor: 3.603
Authors: Pere Gascón; José Almenárez; Ángel Artal; Carlos Camps; José Luis Fírvida; Pilar Garrido; José Luis González Larriba; Joaquín Montalar Journal: Clin Transl Oncol Date: 2011-05 Impact factor: 3.405
Authors: Maen Hussein; Marina Maglakelidze; Donald A Richards; Marielle Sabatini; Todd A Gersten; Keith Lerro; Ivan Sinielnikov; Alexander Spira; Yili Pritchett; Joyce M Antal; Rajesh Malik; J Thaddeus Beck Journal: Cancer Manag Res Date: 2021-08-09 Impact factor: 3.989
Authors: Lorenzo Gianni; Bernard F Cole; Ilaria Panzini; Raymond Snyder; Stig B Holmberg; Michael Byrne; Diana Crivellari; Marco Colleoni; Stefan Aebi; Edda Simoncini; Olivia Pagani; Monica Castiglione-Gertsch; Karen N Price; Aron Goldhirsch; Alan S Coates; Alberto Ravaioli Journal: Support Care Cancer Date: 2007-07-13 Impact factor: 3.603
Authors: J L Steegmann; J M Sánchez Torres; R Colomer; Á Vaz; J López; I Jalón; M Provencio; A González-Martín; M Pérez Journal: Clin Transl Oncol Date: 2012-12-19 Impact factor: 3.405